 The stock price of Allogene Therapeutics, a biotechnology company focused on T-cell therapies for solid tumors, has seen an 18 rise over the last month, white its down 38 YTD. The stock price over the recent weeks has been buoyed by the U.S. FDA assigning fast track designation to its ALLO-316. 